Share on StockTwits

Osiris Therapeutics (NASDAQ:OSIR) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report released on Friday. The firm currently has a $19.00 price target on the stock. Zacks‘s price target points to a potential upside of 20.71% from the company’s current price.

Zacks’ analyst wrote, “Osiris reported a loss of $0.02 per share in the first quarter, a penny wider than the year-ago loss of $0.01 per share but narrower than the Zacks Consensus Estimate of a loss of $0.08 per share. Revenues for the quarter came in at $10.1 million, surpassing the Zacks Consensus Estimate of $9 million and increasing 146% from the year-ago quarter. Revenues increased 25% sequentially reflecting higher volume. Osiris reported sales growth for Grafix as well as Ovation. Osiris’ Biosurgery segment has been gaining traction over the past few quarters and is well-positioned for growth. The company’s increased sales effort should start paying off from the second half of the year. We are also positive on the company’s sale of its ceMSC business. Based on the company’s attractive growth prospects, we are upgrading the stock to Outperform. “

In other Osiris Therapeutics news, Insider Matthew Paul Neumayer sold 3,750 shares of the stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $16.10, for a total transaction of $60,375.00. The sale was disclosed in a filing with the SEC, which is available at this link.

Several other analysts have also recently commented on the stock. Analysts at TheStreet downgraded shares of Osiris Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, March 17th.

Shares of Osiris Therapeutics (NASDAQ:OSIR) traded down 1.73% on Friday, hitting $15.467. 51,535 shares of the company’s stock traded hands. Osiris Therapeutics has a 52-week low of $10.00 and a 52-week high of $27.40. The stock’s 50-day moving average is $14.36 and its 200-day moving average is $15.2. The company has a market cap of $529.3 million and a P/E ratio of 12.31.

Osiris Therapeutics (NASDAQ:OSIR) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.02) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.08) by $0.06. Analysts expect that Osiris Therapeutics will post $0.01 EPS for the current fiscal year.

Osiris Therapeutics, Inc (NASDAQ:OSIR), is a stem cell therapeutic company.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.